Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sovleplenib · HMPL-523

Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Hutchmed

Phase 2/3 Most advanced trial
HCM Developer
3 Registered trials

What is Sovleplenib?

Sovleplenib is an orally available inhibitor of spleen tyrosine kinase (SYK), a non-receptor tyrosine kinase associated with the B-cell receptor. By blocking SYK it inhibits B-cell receptor signaling, B-cell activation and tumor cell proliferation. It is studied in warm antibody autoimmune hemolytic anemia and primary immune thrombocytopenia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HMPL-523
Drug type
Small molecule
Targets
spleen tyrosine kinase (SYK)
Mechanism
Inhibitor of spleen tyrosine kinase (SYK)
Pathways
B-cell receptor signaling, B-cell activation, tumor cell migration, adhesion and proliferation
Therapy area
Hematology, Immunology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
9CL6353KHO

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05535933 Phase 2/3 Warm Antibody Autoimmune Hemolytic Anemia Active not recruiting HCM
NCT05029635 Phase 3 Primary Immune Thrombocytopenia (ITP) Completed HCM
NCT07331194 Phase 1 Healthy Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Warm Antibody Autoimmune Hemolytic AnemiaHealthyPrimary Immune Thrombocytopenia (ITP)

Other drugs acting on SYK

More from Hutchmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind Sovleplenib

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.